×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Hypothesis: APOE contributes to Alzheimer's disease by regulating both b
hypothesis
2,704 words
Contents
APOE contributes to Alzheimer's disease by regulating both beta-amyloid deposition
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (78)
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.68
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Complement C1q Subtype Switching
Score: 0.66
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.66
Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.66
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.62
Sphingolipid Metabolism Reprogramming
Score: 0.62
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
Netrin-1 Gradient Restoration
Score: 0.59
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.43
Piezoelectric Nanochannel BBB Disruption
Score: 0.52
← Prev
pg 4/4
Related Analyses (30)
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
Lipid metabolism dysregulation and membrane integrity in Alz
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Show 25 more
Related Experiments (30)
Meta-analysis of LRP1 C766T polymorphism and Alzheimer's dis
exploratory · proposed · Score: 0.95
Dairy intake and dementia risk in Malmö Diet and Cancer coho
clinical · proposed · Score: 0.95
KEEPS Continuation: Long-term effects of menopausal hormone
clinical · proposed · Score: 0.95
GWAS of plasma pTau217 in East Asian cohort
exploratory · proposed · Score: 0.95
GWAS of plasma GFAP in East Asian cohort
exploratory · proposed · Score: 0.95
GWAS of plasma NfL in East Asian cohort
exploratory · proposed · Score: 0.95
GWAS of plasma pTau181 in East Asian cohort
exploratory · proposed · Score: 0.95
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
GWAS of composite biomarker score
exploratory · proposed · Score: 0.90
APOE4 association with TDP-43 pathology in AD
exploratory · proposed · Score: 0.75
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
Real-world safety study of Lecanemab in Japanese AD patients
clinical · proposed · Score: 0.95
DDT/DDE exposure and cognitive function in Latina women
clinical · proposed · Score: 0.90
DLB Treatment Response Biomarkers — Predicting Cholinesteras
clinical · proposed · Score: 0.40
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
s:** - Biochemical binding assays measuring PROTAC selectivi
falsification · proposed · Score: 0.40
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Biomechanical Impact Profiles and Chronic Traumatic Encephal
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Olfactory Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Neurogranin - Alzheimer's Disease Biomarker
biomarker · Pages share 18 hypotheses
Dried Blood Spot Biomarker Test for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
DTI Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Ocular Fluid Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Digital Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
ASL Perfusion Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Eye-Tracking Digital Markers in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Gait Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
GFAP in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Inflammatory Biomarkers in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
EEG Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Alzheimer's Disease Biomarkers
biomarker · Pages share 18 hypotheses
Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer
biomarker · Pages share 18 hypotheses
Show 10 more
Knowledge Graph (8 edges)
Therapeutics
references
APOE
Mechanisms
references
APOE
Therapy Ideas
references
APOE
Disease-Modifying Therapies for Alzheimer's Disease
references
APOE
UB-311 Alzheimer's Vaccination Trial
references
APOE
VY7523 Phase 1/2 Alzheimer's Disease Trial
references
APOE
nct05531526
references
APOE
MK-1167 Phase 2 AD Trial (MK-1167-008)
references
APOE
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.